Literature DB >> 16426698

Accumulation of dysfunctional effector CD8+ T cells in the liver of patients with chronic HCV infection.

Carla Nisii1, Massimo Tempestilli, Chiara Agrati, Fabrizio Poccia, Guido Tocci, Maria Antonella Longo, Gianpiero D'Offizi, Roberto Tersigni, Oreste Lo Iacono, Giorgio Antonucci, Alessandra Oliva.   

Abstract

BACKGROUND/AIMS: Hepatitis C virus (HCV) causes a chronic infection that can lead to fibrosis and carcinoma. Immune responses mediated by cytotoxic T lymphocytes (CTLs) could be involved in viral clearance or persistence, and therefore in determining the course of the disease.
METHODS: Intrahepatic and peripheral blood CD8+T cells were obtained from 32 HCV-chronically infected patients and analysed by flow-cytometry for surface markers of differentiation, IFNgamma and TNFalpha production, degranulation capacity and perforin content, after CD3 triggering. Results were compared with those obtained from 13 patients with a non-viral liver disease.
RESULTS: Intrahepatic CD8+T cells of HCV-infected patients, despite their phenotype of pre-terminally and terminally differentiated effectors (CCR7-CD45RA-/+), are poorly responsive to T cell receptor (TCR)-mediated stimulation compared with those obtained from uninfected subjects. This defect correlates with the severity of fibrosis, is more pronounced in patients with ALT<1.5xN than with ALT>1.5xNU/ml, and is not evident after mitogen stimulation.
CONCLUSIONS: The present study describes the accumulation of hypo-responsive CD8+T cells in the liver of patients with chronic HCV infection. Understanding the mechanisms underlying this impairment may be helpful in the design of innovative strategies for HCV treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16426698     DOI: 10.1016/j.jhep.2005.10.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.

Authors:  J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench
Journal:  J Viral Hepat       Date:  2010-07-05       Impact factor: 3.728

2.  Preserved MHC-II antigen processing and presentation function in chronic HCV infection.

Authors:  D H Canaday; C J Burant; L Jones; H Aung; L Woc-Colburn; D D Anthony
Journal:  Cell Immunol       Date:  2010-10-16       Impact factor: 4.868

3.  Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?

Authors:  S Lee; T Hammond; M W Watson; J P Flexman; W Cheng; S Fernandez; P Price
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

4.  Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.

Authors:  Jia Liu; Ejuan Zhang; Zhiyong Ma; Weimin Wu; Anna Kosinska; Xiaoyong Zhang; Inga Möller; Pia Seiz; Dieter Glebe; Baoju Wang; Dongliang Yang; Mengji Lu; Michael Roggendorf
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

5.  Immunoproteasome induction is suppressed in hepatitis C virus-infected cells in a protein kinase R-dependent manner.

Authors:  In Soo Oh; Kathrin Textoris-Taube; Pil Soo Sung; Wonseok Kang; Xenia Gorny; Thilo Kähne; Seon-Hui Hong; Young Joon Choi; Clemens Cammann; Michael Naumann; Jong Hoon Kim; Su-Hyung Park; Ook Joon Yoo; Peter M Kloetzel; Ulrike Seifert; Eui-Cheol Shin
Journal:  Exp Mol Med       Date:  2016-11-11       Impact factor: 8.718

6.  Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection.

Authors:  Sang-Jun Ha; Scott N Mueller; E John Wherry; Daniel L Barber; Rachael D Aubert; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  J Exp Med       Date:  2008-03-10       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.